Novartis Plans Fast Entresto Launch Following FDA Approval
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.